Patents by Inventor Orphée Blanchard

Orphée Blanchard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-CCR8 MONOCLONAL ANTIBODIES AND THEIR THERAPEUTIC USE
    Publication number: 20260337283
    Abstract: The present invention relates to a monoclonal antibody or an antigen-binding fragment thereof, which specifically binds to human CCR8 and is an antagonist of the CCL1-CCR8 signaling pathway, particularly wherein the antibody or antigen-binding fragment specifically binds to human CCR8 independently from the presence or absence of post-translational modifications, such as sulfated tyrosine residues at the positions 15, 16 and/or 17 of human CCR8. The invention also relates to the antibody or antigen-binding fragment for use in therapy, particularly in the treatment of cancer.
    Type: Application
    Filed: September 20, 2024
    Publication date: October 29, 2026
    Applicant: DOMAIN THERAPEUTICS
    Inventors: Christel FRANCHET, Alice GENTIL DIT MAURIN, Dounia CHRAA, Iseulys RICHERT, Orphée BLANCHARD, Xavier LEROY, Claudine VERMOT-DESROCHES, Julien ISOARD, Yannick NIZET
  • ANTI-CCR8 MONOCLONAL ANTIBODIES AND THEIR THERAPETUIC USE
    Publication number: 20260327319
    Abstract: The present invention relates to a monoclonal antibody or an antigen-binding fragment thereof, which specifically binds to human CCR8 and is an antagonist, particularly an insurmountable antagonist, of the CCL1-CCR8 signaling pathway. The invention also relates to the antibody or antigen-binding fragment for use in therapy, particularly in the treatment of cancer.
    Type: Application
    Filed: September 20, 2024
    Publication date: October 22, 2026
    Applicant: DOMAIN THERAPEUTICS
    Inventors: Dounia CHRAA, Iseulys RICHERT, Luc BARON, Christel FRANCHET, María Dolores GARCÍA FERNÁNDEZ, Malaury SCHAPPLER, Nathalie LENNE, Orphée BLANCHARD, Xavier LEROY, Claudine VERMOT-DESROCHES, Julien ISOARD, Yannick NIZET
  • ANTI-CCR8 MONOCLONAL ANTIBODIES AND THEIR THERAPEUTIC USE
    Publication number: 20260234276
    Abstract: The present invention relates to a monoclonal antibody or an antigen-binding fragment thereof, which specifically binds to human CCR8 and is an antagonist of the CCL1-CCR8 signaling pathway, particularly wherein the antibody or antigen-binding fragment has an antagonistic activity on the CCL1-CCR8 signaling pathway at a pH of 6.2 to 6.9, which is indicative of the acidic pH of the tumor microenvironment. The invention also relates to the antibody or antigen-binding fragment for use in therapy, particularly in the treatment of cancer.
    Type: Application
    Filed: September 21, 2023
    Publication date: August 13, 2026
    Applicant: Domain Therapeutics
    Inventors: Orphée BLANCHARD, Xavier LEROY, Claudine VERMOT-DESROCHES, Julien ISOARD, Yannick NIZET
  • ANTI-CCR8 MONOCLONAL ANTIBODIES AND THEIR THERAPEUTIC USE
    Publication number: 20260167731
    Abstract: The present invention relates to a monoclonal antibody or an antigen-binding fragment thereof, which specifically binds to human CCR8 and is an antagonist of the CCL1-CCR8 signaling pathway, particularly wherein the antibody or antigen-binding fragment specifically binds to human CCR8 independently from the presence or absence of post-translational modifications, such as sulfated tyrosine residues at the positions 15, 16 and/or 17 of human CCR8. The invention also relates to the antibody or antigen-binding fragment for use in therapy, particularly in the treatment of cancer.
    Type: Application
    Filed: September 21, 2023
    Publication date: June 18, 2026
    Applicant: Domain Therapeutics
    Inventors: Christel FRANCHET, Alice GENTIL DIT MAURIN, Dounia CHRAA, Iseulys RICHERT, Orphée BLANCHARD, Xavier LEROY, Claudine VERMOT-DESROCHES, Julien ISOARD, Yannick NIZET
  • ANTI-CCR8 MONOCLONAL ANTIBODIES AND THEIR THERAPEUTIC USE
    Publication number: 20260132208
    Abstract: The present invention relates to a monoclonal antibody or an antigen-binding fragment thereof, which specifically binds to human CCR8 and is an antagonist, particularly an insurmountable antagonist, of the CCL1-CCR8 signaling pathway. The invention also relates to the antibody or antigen-binding fragment for use in therapy, particularly in the treatment of cancer.
    Type: Application
    Filed: September 21, 2023
    Publication date: May 14, 2026
    Applicant: Domain Therapeutics
    Inventors: Christel FRANCHET, María Delores GARCÍA FERNÁNDEZ, Malaury SCHAPPLER, Nathalie LENNE, Orphée Blanchard, Xavier LEROY, Claudine Vermot-Desroches, Julien ISOARD, Yannick NIZET